Merck stock rises 2.1 percent ahead of the open

At the close on September 21, 2026, Merck stock reached USD 149.90 after trading as high as USD 149.93. Japan approved a subcutaneous Keytruda formulation for all approved indications.

Merck stock closed at USD 149.90 on the New York Stock Exchange on September 21, 2026, gaining 2.1 percent. The Dow Jones Industrial Average stood at 52,062 points in the late session, while Merck traded at USD 149.90, according to finanzen.ch data. GuruFocus reported that Japanese regulators approved Keytruda Qlex for all previously approved indications on September 21, 2026.

September 21, 2026 in numbers

Merck & Co., Inc. (ISIN US58933Y1055, NYSE: MRK) reached an intraday high of USD 149.93 and closed at USD 149.90 on September 21, 2026. The session volume was 427,910 shares, while the quoted session low was not provided in the dated market report. The stock remained USD 7.01 below its 52-week high of USD 156.91, a gap of 4.47 percent.

The quoted close was USD 3.68 below the 52-week high and USD 72.32 above the 52-week low of USD 77.58. Merck gained 2.1 percent in the session, compared with a 0.71 percent rise for the Dow Jones Industrial Average at 52,062 points in the late-session comparison.

Keytruda approval supports today focus

Japan's Ministry of Health, Labor and Welfare approved the subcutaneous Keytruda Qlex injection across all previously approved indications, according to GuruFocus. The next quarterly results are scheduled for October 29, 2026, according to finanzen.ch.